Genmab GMAB

NAS: GMAB | ISIN: US3723032062   26/04/2024
28,15 USD (+2,51%)
(+2,51%)   26/04/2024

22 april 2024 · Transactions in Connection with Share Buy-back Program Genmab · Persbericht

16 april 2024 · Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2024 · Persbericht

15 april 2024 · Transactions in Connection with Share Buy-back Program Genmab · Persbericht

8 april 2024 · Transactions in Connection with Share Buy-back Program · Persbericht

3 april 2024 · Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio · Persbericht

2 april 2024 · Transactions in Connection with Share Buy-back Program · Persbericht

25 maart 2024 · Transactions in Connection with Share Buy-back Program · Persbericht

18 maart 2024 · Completion of share buy-back program · Persbericht

15 maart 2024 · Genmab Announces Initiation of Share Buy-Back Program · Persbericht

13 maart 2024 · Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons · Persbericht

13 maart 2024 · Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab · Persbericht

13 maart 2024 · Passing of Genmab A/S’ Annual General Meeting · Persbericht

11 maart 2024 · Transactions in connection with share buy-back program · Persbericht

4 maart 2024 · Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons · Persbericht

4 maart 2024 · Transactions in connection with share buy-back program · Persbericht

2 maart 2024 · Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons · Persbericht

29 februari 2024 · Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons · Persbericht

27 februari 2024 · Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons · Persbericht

27 februari 2024 · Capital Increase in Genmab as a Result of Employee Warrant Exercise · Persbericht

27 februari 2024 · U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma · Persbericht

Mijn selecties